ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Gut Lactate Boosts Ruminococcus via Histone Lactylation to Mediate Time-Restricted Feeding Protection in Crohn's Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundCrohn's disease (CD) is characterized by impaired epithelial barrier function and dysregulated gut microbiota, particularly characterized by a reduced abundance of short-chain fatty acid (SCFA)-producing bacteria such as Ruminococcus. Time-restricted feeding (TRF), which limits daily food intake to specific feeding windows, has been demonstrated to restore microbial balance, enrich SCFA-producing bacteria, and enhance gut homeostasis. Nevertheless, the extent to which TRF confers protection against CD, as well as the mechanisms underlying this effect, remains largely unexplored.
methodsFecal samples were obtained from patients with active CD and from healthy control subjects to quantify the abundance of Ruminococcus. Using 16S rRNA sequencing, we examined the impact of TRF regimens with varying fasting/feeding cycles (12/12, 16/8, and 20/4) on Ruminococcus. In preclinical CD models, we systematically evaluated the protective effect of TRF by analyzing colonic inflammation and fibrosis using histopathological techniques. RNA-seq and epigenetic analyses were performed to elucidate the underlying mechanisms.
resultsFecal Ruminococcus abundance was significantly reduced in patients with CD and inversely correlated with disease activity indices. Among the tested regimens, only the 12/12 fasting/feeding regimen (TRF_12h), but not regimens with shorter feeding windows, robustly increased the Ruminococcus abundance and potently stimulated mitochondrial β-oxidation and lactate generation. Preemptive administration of TRF_12h markedly protected against colitis severity and fibrosis in CD models, as evidenced by marked reductions in F4/80
conclusionsCollectively, TRF enriches SCFA-producing Ruminococcus through a gut lactate-driven histone lactylation-SLC9A3 signaling axis, thereby alleviating inflammation and fibrosis in Crohn's disease under preventive conditions. Ruminococcus-derived SCFA further enhances epithelial mitochondrial β-oxidation and activates HIF-1α-dependent signaling pathways to strengthen the barrier integrity. This study provides a compelling mechanistic foundation for the clinical exploration of TRF as a therapeutic dietary strategy for patients with CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.